November 21st 2024
The country’s program yielded screening and treatment in almost two thirds of the identified at-risk population.
Where to Treat Uncomplicated HCV? Assessing the Impact of Shifting Care From Specialists to PCPs
October 8th 2019One promising proposal to greatly increase access to DAA HCV therapy is to keep this treatment with appropriately trained PCPs, in contrast with referring patients to infectious disease, gastroenterology, or hepatology subspecialists.
Read More
Hepatitis C Virus Retreatment Successful with SOF/VEL/VOX in Patients With and Without HIV
November 13th 2018A fixed-dose combination therapy (Vosevi, Gilead) was highly effective after 12 weeks in retreating direct-acting antiviral-experienced patients with hepatitis C virus infection, with and without HIV co-infection, including those with prior noncompletion of treatment or poor adherence.
Read More
Direct-Acting Antiviral Therapy Effective for Curing Hepatitis C in Injection Drug Users
September 24th 2018A recent study by the Kirby Institute reported that after using direct-acting antiviral therapy 97% of participants with HCV who recently used injectable drugs achieved sustained viral response.
Read More